News Search Results
Mar 24, 2025, 18:04 ET Investor Alert: Robbins LLP Informs Investors of the Sana Biotechnology, Inc. Class Action Lawsuit
treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
More news about: Robbins LLP
Mar 24, 2025, 10:00 ET Corero Network Security Earns Spot in the 2025 CRN® Partner Program Guide
Corero Network Security (AIM: CNS) (OTCQX: DDoSF), the distributed denial of service (DDoS) protection specialists, has been honored by
More news about: Corero Network Security
Mar 24, 2025, 09:00 ET Cohen & Steers Real Estate Securities Fund Receives LSEG Lipper Performance Award
YORK, March 24, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that the Cohen & Steers Real Estate Securities Fund (
More news about: Cohen & Steers, Inc.
Mar 24, 2025, 08:00 ET Pathios Therapeutics Appoints Sumeet Ambarkhane, M.D., as Chief Medical Officer
Appointment Aligns with Company's Ongoing Maturation as Lead Cancer Program Progresses Through First-in-Human Study and Preclinical Activities for CNS Indications Advance Dr. Sumeet Ambarkhane Will Guide Development of First-in-class Oncology Program Based on Genetically
More news about: Pathios Therapeutics
Mar 21, 2025, 08:05 ET Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Mar 20, 2025, 14:53 ET The International Society for CNS Drug Development (ISCDD) Honors Sharon Mates, PhD, and Steven Paul, MD with Prestigious Leadership Award at 23rd Annual Meeting
acknowledge Sharon's impact on CNS drug development over many decades." "Dr. Steven Paul has been singularly successful in developing multiple new breakthrough treatments for patients. It is our honor to acknowledge his impact in CNS drug development over many decades."
More news about: International Society for CNS Drug Development
Mar 20, 2025, 14:06 ET Senior Helpers East San Diego Achieves Prestigious CHAP Age-Friendly Care at Home Certification
Certification was a logical next step." Owners, Jung Yi, MD, RCFE, Cassia Yi, APRN, CNS-BC, MSN, CCRN, and Maureen Mostella, RCFE, stated, "Being certified in Age-Friendly Care is a testament to our commitment
More news about: Senior Helpers
Mar 20, 2025, 09:15 ET Newly Published Epilepsia Supplement Highlights Potential of Third Generation Antiseizure Medications to Help More Patients Achieve Seizure Freedom
SK Life Science, Inc., a U.S. pharmaceutical company developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced the publication of a sponsored supplement to Epilepsia, the leading
More news about: SK Life Science, Inc.
Mar 19, 2025, 07:30 ET Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
combination with other CNS depressants, isassociated with CNS adverse reactions, including seizure, respiratory depression,decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse
More news about: Jazz Pharmaceuticals plc
Mar 18, 2025, 09:00 ET Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA® in Treating Large Hemispheric Infarction, Including Wake-Up Strokes
held, clinical-stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) injuries. Contact: Sven Jacobson CEO Remedy Pharmaceuticals 212.586.2226
More news about: Remedy Pharmaceuticals
Mar 18, 2025, 04:00 ET Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Formosa Pharmaceuticals Inc.,
Mar 17, 2025, 17:31 ET VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight
Taletrectinib (AB-106/IBI-344) is a next-generation, selective ROS1 inhibitor designed for treating advanced ROS1-positive NSCLC. It is an oral, potent, and CNS-active therapy currently being evaluated in two pivotal Phase II single-arm studies: TRUST-I (NCT04395677) in China
More news about: DelveInsight Business Research, LLP
Mar 17, 2025, 10:00 ET Clario announces acquisition of imaging provider NeuroRx
Douglas Arnold, NeuroRx is an imaging provider with an unparalleled expertise in diseases impacting the Central Nervous System ("CNS"), such as multiple sclerosis, Huntington's, Parkinson's, Alzheimer's, and other rare neurological diseases. Since its founding, NeuroRx has supported
More news about: Clario
Mar 17, 2025, 10:00 ET Clario announces acquisition of imaging provider NeuroRx
Douglas Arnold, NeuroRx is an imaging provider with an unparalleled expertise in diseases impacting the Central Nervous System ("CNS"), such as multiple sclerosis, Huntington's, Parkinson's, Alzheimer's, and other rare neurological diseases. Since its founding, NeuroRx has supported
More news about: Clario
Mar 17, 2025, 08:02 ET NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
use – in the manner that diabetes drugs are currently administered – could facilitate far broader clinical use of ketamine to treat life-threatening CNS diseases. The Company has retained a leading regulatory law firm to file the citizen's petition with the US Food and Drug Administration to remove
More news about: NRx Pharmaceuticals, Inc.
Mar 17, 2025, 06:00 ET Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
innovation and strategic partnerships, the company is advancing a diverse portfolio of programs targeting respiratory diseases, central nervous system (CNS) disorders, and fibrotic diseases. For more information, please visit www.chancepharmaceuticals.com.
More news about: Chance Pharmaceuticals
Mar 13, 2025, 16:05 ET Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
additional data from the ongoing Phase 1a/b trial in the middle of 2025.ELVN-002 is a potent, highly selective, central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations Enliven continued
More news about: Enliven Therapeutics, Inc.
Mar 13, 2025, 08:00 ET Lipocine Announces Financial Results for the Full Year Ended December 31, 2024
2024, Lipocine announced positive data from a quantitative EEG (qEEG) study of oral brexanolone. The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentration- and time-dependent post-dose changes in qEEG. These results confirm GABAA positive allosteric
More news about: Lipocine Inc.
Mar 13, 2025, 07:00 ET Corero Network Security Accelerates AI Integration with Focus on Substance Over Hype
Mass., March 13, 2025 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the DDoS protection specialists, today announced the strategic advancement of AI capabilities across its product portfolio and operations—building
More news about: Corero Network Security
Mar 12, 2025, 17:31 ET ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
valuable market segment. While competition from other TRK inhibitors, such as larotrectinib (VITRAKVI), may influence growth, its ability to penetrate the CNS provides a distinct advantage. LAS VEGAS,
More news about: DelveInsight Business Research, LLP
Mar 12, 2025, 13:54 ET Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
is observed. Somnolence, Sedation, and Lethargy: FINTEPLA can cause somnolence, sedation, and lethargy. Other central nervous system (CNS) depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should
More news about: UCB
Mar 11, 2025, 16:01 ET Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano
More news about: Neurocrine Biosciences, Inc.
Mar 11, 2025, 07:45 ET Axxess Highlights 2025 AGILE Distinction Awards Finalists
Hospice - SOMCThe Compliance Standards of Excellence Award finalists are: BSA ComPassion Home Care, CSRA (Central Savannah River Authority), CNS Cares, BeyondFaith Hospice, Tillery Compassionate Care, Hosparus HealthWinners of the AGILE Distinction Awards will be announced during
More news about: Axxess
Mar 10, 2025, 16:35 ET Cohen & Steers Announces the Retirement of Daniel P. Charles, Head of Global Distribution
YORK, March 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Daniel P. Charles, Executive Vice President and Head of Global Distribution, will retire after 37
More news about: Cohen & Steers, Inc.
Mar 10, 2025, 16:24 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for February 2025
YORK, March 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of February 28, 2025,
More news about: Cohen & Steers, Inc.